Looking to sell Synchron stock or options?
Synchron has developed an implantable stentrode aimed at establishing a brain-computer interface. This innovative company provides a minimally invasive device equipped with electrode arrays that decode brain signals to influence neural activity in targeted areas. This technology empowers patients with motor impairments to regain some control over digital devices, prosthetics, or other assistive technologies using just their thoughts.
Bezos Expeditions, Project X, Greenoaks Capital Partners, Arani Bose, Moore Strategic Ventures, Forepont Capital Partners, Metis Innovative, re.Mind Capital, Defense Advanced Research Projects Agency, Thomas Reardon, United States Department of Defense, MTPConnect, ARCH Venture Partners, Khosla Ventures, National Institutes of Health, Mind Capital, Green Sands Equity, General Advance, Reliance Digital Health, The University of Melbourne Endowment, Gates Family Foundation, Jumpspace Ventures, ID8 Investments, Shanda Group, Alumni Ventures.
Synchron is currently a private company. This means that the company is not listed on any public exchange and so there is no public market for its stock. However, there may still be ways to monetize Synchron stock. Depending on Synchron’s policies, you may be able to: (1) find a private buyer in the secondary market to purchase your stock, (2) borrow against your stock, or (3) exchange Synchron stock into the Collective Exchange Fund for a limited partnership interest and then borrow non-recourse against your interest to generate immediate cash. This last alternative can be much quicker and net you more after-tax cash than your other options. An exchange into our fund also reduces your risk by diversifying your holdings out of an over-concentrated position.
Collective Liquidity can provide liquidity to shareholders of Synchron stock in two ways. First, Synchron employees can exchange shares into the Collective Exchange Fund and then borrow non-recourse to generate immediate cash. This can net you more after-tax cash than a stock sale. It also reduces your risk by diversifying your holdings out of an over-concentrated position. In some cases, Collective may also be able to purchase your Synchron stock. Note that all transactions in Synchron shares are subject to the company’s policies regarding secondary transactions. Schedule a call with a Collective Liquidity representative to learn more about your private market liquidity alternatives.
Synchron stock is not listed on any public exchange and so there is no public market for its shares. Therefore, there is no single, centralized price for Synchron stock. Typically, shares of private companies like Synchron are set with buyers in one off negotiations. Collective Liquidity, however, uses a proprietary algorithm to determine its bids so we almost always have an immediately actionable price for you.
On Dec 2022, Synchron is reported to have closed an equity financing in which the investors valued the company at $401M. This valuation is typically calculated by multiplying the per share price of the preferred stock sold in the financing by the number of Synchron shares outstanding assuming the conversion of all stock options, warrants, etc.
Tickers are used to identify company’s shares on public markets like the NYSE or Nasdaq. Because Synchron is not currently publicly traded, it does not have a ticker symbol.
Synchron has not yet conducted an initial public offering (“IPO”) and so remains a private company. Though Synchron is a well-known, successful company, there can be no assurance that it will ever go public or be sold. Because of the risk this imposes on Synchron shareholders, many investors elect to gain liquidity for at least some of their shares before the IPO. Schedule a call with a Collective Liquidity representative to discuss your private market liquidity alternatives.